Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia

J Clin Oncol. 2013 Apr 20;31(12):e197-9. doi: 10.1200/JCO.2012.46.9593. Epub 2013 Mar 18.

Authors

Britt M Holderness¹, Saurabh Malhotra, Norman B Levy, Alexey V Danilov

Affiliation

¹ Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756, USA. [email protected]

PMID: 23509308
DOI: 10.1200/JCO.2012.46.9593

No abstract available

Publication types

Case Reports

MeSH terms

Brentuximab Vedotin
Humans
Immunoconjugates / immunology
Immunoconjugates / metabolism*
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Lymphoma, Large-Cell, Immunoblastic / etiology
Lymphoma, Large-Cell, Immunoblastic / metabolism*
Lymphoma, Large-Cell, Immunoblastic / pathology
Male
Middle Aged
Multimodal Imaging
Positron-Emission Tomography
Prognosis
Tomography, X-Ray Computed

Substances

Immunoconjugates
Brentuximab Vedotin